Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing

Family Practice

Volumn 30, Issue 6, 2013, Pages 648-654

  Hamoen, Esther H J ^a   Reukers, Daphne F M ^a   Numans, Mattijs E ^b,c   Barentsz, Jelle O ^a   Witjes, J Alfred ^a   Rovers, Maroeska M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnostic test; Epidemiology; Incidence; Mass screening; Prostate specific antigen; Prostatic neoplasms.

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTHROPATHY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST; GENERAL PRACTICE; HEALTH CARE UTILIZATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OBESITY; PRACTICE GUIDELINE; PROSTATE SPECIFIC ANTIGEN TEST; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; URINARY TRACT DISEASE;

DIAGNOSTIC TEST; EPIDEMIOLOGY; INCIDENCE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS.;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84888142430     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cmt045     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. American Cancer Society. What Are the Key Statistics About Prostate Cancer? www.cancer.org. (accessed on November 2012).
3. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178(3 Pt 2): S14-9.
4. Payne H, Cornford P. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol 2011; 29: 593-601.
5. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-52.
6. Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, Walker M. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol 2009; 9: 14.
7. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46.
8. Andriole GL, Crawford ED, Grubb RL 3rd et al.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9.
9. Schröder FH, Hugosson J, Roobol MJ et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
10. Chou R, Croswell JM, Dana T et al. Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155: 762-71. doi:10.7326/0003-4819-155-11-201112060-00375.
11. Heidenreich A, Bellmunt J, Bolla M et al.; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
12. Blanker MH, Breed SA, van der Heide WK et al. Guideline lower urinary tract symptoms in men. Huisarts Wet 2013; 56: 114-22.
13. Drummond FJ, Carsin AE, Sharp L, Comber H. Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Ir J Med Sci 2010; 179: 43-9.
14. Jonsson H, Holmström B, Duffy SW, Stattin P. Uptake of prostatespecific antigen testing for early prostate cancer detection in Sweden. Int J Cancer 2011; 129: 1881-8.
15. Nordstrom T, Aly M, Clements MS, Weibull CE, Adolfsson J, Gronberg H. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population- based study, 2003-2011. Eur Urol 2013; 63: 419-25.
16. Crawford ED, Grubb R 3rd, Black A et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011; 29: 355-61.
17. Grobbee DE, Hoes AW, Verheij TJ, Schrijvers AJ, van Ameijden EJ, Numans ME. The Utrecht Health Project: optimization of routine healthcare data for research. Eur J Epidemiol 2005; 20: 285-7.
18. Akkerman A, Verheij T, Veen R, Grobbee D, Hak E. Interactieve medische informatie van het Huisartsen Netwerk Utrecht en de Almere Zorggroep. (Interactive medical information from the General Practitioners Network Utrecht and the Almere Healthcare group). Huisarts en wetenschap 2008; 51: 90-5.
19. Smith DP, Supramaniam R, Marshall VR, Armstrong BK. Prostate cancer and prostate-specific antigen testing in New South Wales. Med J Aust 2008; 189: 315-8.
20. Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA 2012; 307: 1692-4.
21. Melia J, Moss S, Johns L; Contributors in the participating laboratories. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004; 94: 51-6.
22. Williams N, Hughes LJ, Turner EL et al. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. BJU Int 2011; 108: 1402-8.
23. Finney Rutten LJ, Meissner HI, Breen N, Vernon SW, Rimer BK. Factors associated with men's use of prostate-specific antigen screening: evidence from Health Information National Trends Survey. Prev Med 2005; 40: 461-8.
24. Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med 2007; 167: 2497-502.
25. Van der Meer S, Kollen BJ, Hirdes WH et al. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners. BJU Int 2013; 112: 26-31. doi:10.1111/ bju.12029.
26. Schaeffer EM, Carter HB, Kettermann A, et al. Prostate specific antigen testing among the elderly-when to stop? J Urol 2009; 181: 1606-14; discussion 1613-1604.
27. Roobol MJ, Kirkels WJ, Schröder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 2003; 92 (suppl 2): 48-54.
28. Wolters RJ, Spigt MG, Van Reedt Dortland PFH, Gercama AJ, Klomp ML. Guideline difficult voiding in older men (second revision). Huisarts Wet 2004; 47: 571-86.